Adherence to fingolimod in multiple sclerosis patients taking part in a person-centred integrated care programme in Switzerland

Details

Serval ID
serval:BIB_8315B44B38B3
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Adherence to fingolimod in multiple sclerosis patients taking part in a person-centred integrated care programme in Switzerland
Title of the conference
Multiple Sclerosis Journal
Author(s)
Bourdin Aline, Schneider Marie, Locatelli Isabella, Schluep Myriam, Bugnon Olivier (co-last), Berger Jérôme (co-last)
Publication state
Published
Issued date
2016
Volume
22
Number
53
Pages
339
Language
english
Notes
Poster : P698, abstract publié dans Multiple Sclerosis Journal, vol. 22, n°53, page 339
Abstract
Background: In Switzerland, fingolimod has been approved as a first-line treatment in patients with relapsing-remitting multiple sclerosis (MS). In 2013, the Community Pharmacy of the Department of Ambulatory Care & Community Medicine in Lausanne implemented a person-centred integrated care programme for optimising safety and effectiveness of fingolimod. This routine pharmacist-led programme is proposed to each consecutive patient starting fingolimod at the local University hospital (Centre Hospitalier Universitaire Vaudois, CHUV). It combines motivational interviews, adherence monitoring with an electronic monitor (EM), risk evaluation & mitigation strategies (REMS) and a collaborative practice with the neurologist and the MS-nurse.
Objectives: To describe adherence (persistence and implementation) to fingolimod of patients taking part in the person-centred integrated care programme.
Create date
06/01/2019 15:11
Last modification date
29/01/2021 15:00
Usage data